Synthetic Biologics (SYN) Short Interest Ratio & Short Volume

Short interest is the volume of Synthetic Biologics shares that have been sold short but have not yet been covered or closed out. As of September 30th, investors have sold 392,000 shares of SYN short. 2.49% of Synthetic Biologics' shares are currently sold short. Learn More on Synthetic Biologics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SYN shares currently have a short interest ratio of 2.1. Learn More on Synthetic Biologics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.49% of Synthetic Biologics' floating shares are currently sold short.

Synthetic Biologics saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 392,000 shares, a decline of 9.0% from the previous total of 430,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Synthetic Biologics currently has issued a total of 15,844,000 shares. Some of Synthetic Biologics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Synthetic Biologics currently has a public float of 15,750,000 shares.

2.49% of Synthetic Biologics' shares are currently sold short. Here is how the short interest of companies compare to Synthetic Biologics: OS Therapies Incorporated (3.93%), iBio, Inc. (10.36%), Synaptogenix, Inc. (2.62%), Newron Pharmaceuticals S.p.A. (0.91%), Boundless Bio, Inc. (0.82%), and IGC Pharma, Inc. (1.16%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Corporation ($3.27 billion), Charter Communications, Inc. ($2.66 billion), TC Energy Corporation ($2.53 billion), Coinbase Global, Inc. ($1.83 billion), Lucid Group, Inc. ($1.78 billion), T. Rowe Price Group, Inc. ($1.77 billion), Rivian Automotive, Inc. ($1.69 billion), Zoom Communications, Inc. ($1.35 billion), Williams-Sonoma, Inc. ($1.35 billion), and Roblox Corporation ($1.32 billion). View all of the most shorted stocks.

Short selling SYN is an investing strategy that aims to generate trading profit from Synthetic Biologics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Synthetic Biologics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SYN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SYN, twice per month. The most recent reporting period available is September, 30 2022.